Recently, a study by Maha Abdelmonem et al. found that modulating the PKC/NRF2/Bcl-2 signaling pathway can enhance the clinical efficacy of sitagliptin, improving diabetes-induced testicular dysfunction [47]. Here, NFE2L2 is linked to diabetes mellitus.